C205 - Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies
| Event Time: | Thursday May 9, 2019 7:00 am to 9:00 am |
| Topic(s): | Neuromuscular and Clinical Neurophysiology (EMG), Advanced Practice Provider |
| Director(s): | David Herrmann MD, FAAN |
| Description: | Peripheral neuropathies are common. They may be acquired or inherited and acute, subacute, or chronic. Peripheral neuropathies are increasingly amenable to therapy, but the potential morbidity and cost of therapy is often high, emphasizing the importance of prompt, efficient, and accurate diagnosis, and evidence-based management. The course faculty will provide an overview of the clinical features, classification, diagnosis and management of Guillain-Barre Syndrome (GBS) and its variants, mimics including acute nutritional neuropathies and chronic inflammatory demyelinating polyneuropathy (CIDP). This program complements Peripheral Neuropathy II: Update on Diabetic, Immune Axonal, and Hematologic-related Neuropathies and Peripheral Neuropathy III: Genetic Neuropathies: Molecular Diagnosis and Treatment Perspectives, but covers independent topics. |
| Completion Message: | Participants should be able to describe the clinical features, diagnostic approach/criteria and treatment paradigms for Guillain-Barre syndrome and its variants, acute nutritional neuropathies, and CIDP. |
| CME Credits: | 2 |
| Core Competencies: | Patient Care, Medical Knowledge |
| Start/End Time | Title | Faculty |
|---|---|---|
| 7:00 AM - 7:05 AM | Introduction | David N. Herrmann MD, FAAN |
| 7:05 AM - 7:40 AM | Guillain-Barre Syndrome | David N. Herrmann MD, FAAN |
| 7:40 AM - 8:10 AM | Acute Nutritional Neuropathies | Eric L. Logigian MD, FAAN |
| 8:10 AM - 8:40 AM | Chronic Inflammatory Demyelinating Polyneuropathy | Peter Dunbar Creigh MD |
| 8:40 AM - 9:00 AM | Questions and Answers | Faculty |
| Speaker | Disclosure |
|---|---|
| Peter Dunbar Creigh, MD | Dr. Creigh has nothing to disclose. |
| David N. Herrmann, MD, FAAN | Dr. Herrmann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Guidepoint Global, GLG, Alnylam, Neurogene, Regenacy, Inc., Sarepta, Slingshot Insights, Clear View Health Partners, Trinity Partners, Schlesinger, Human First Therapeutics, and Narrow River Management. Dr. Herrmann has received royalty, license fees, or contractual rights payments from University of Rochester. Dr. Herrmann has received research support from Acceleron Pharma. |
| Eric L. Logigian, MD, FAAN | Dr. Logigian has nothing to disclose. |
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 7:00 AM-9:00 AM |
|---|
|
C243 -
Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis
Michael Weiss MD, FAAN |
|
C247 -
What Do I Do Now?: Emergency and Inpatient Management of Migraine and Other Headache Disorders
Stephanie Nahas MD, FAAN |
| 9:15 AM-11:30 AM |
|
Neurology Year in Review Plenary Session
Martinson Arnan MD |
| 1:00 PM-3:00 PM |
|
S58 -
Therapeutics in Neuromuscular Disorders
|
| 2:00 PM-2:45 PM |
|
Consensus-based Care Recommendations for Adults with Myotonic Dystrophy Type 1
Nicholas Johnson MD, FAAN |
|
Consensus-Based Care Recommendations for Adults with haha
|